ICAD inhibitors belong to a significant chemical class that plays a crucial role in regulating DNA fragmentation during apoptosis, or programmed cell death. The acronym ICAD stands for Inhibitor of Caspase-Activated DNase, which provides an insightful glimpse into the function of these compounds. Caspase-Activated DNase (CAD) is an enzyme responsible for cleaving DNA into fragments during apoptosis, a process vital for eliminating damaged or unnecessary cells in multicellular organisms. ICAD inhibitors are a specialized group of molecules designed to modulate the activity of CAD. Structurally, these inhibitors are characterized by their capacity to bind and inactivate ICAD, the natural inhibitor of CAD. ICAD functions as a chaperone that binds to CAD and keeps it in an inactive state.
When apoptosis is triggered, caspases are activated, and they cleave ICAD, thereby releasing CAD and allowing it to fragment DNA. ICAD inhibitors, by blocking this cleavage or altering ICAD's interaction with CAD, can regulate DNA fragmentation, potentially influencing the overall outcome of apoptosis in a controlled manner. Research into ICAD inhibitors has garnered interest due to their potential to shed light on the intricate mechanisms underlying apoptosis and cellular homeostasis. By manipulating the delicate balance between CAD and its inhibitor ICAD, scientists aim to decipher the precise molecular cues that dictate whether a cell undergoes apoptosis or survives. Understanding these mechanisms could provide valuable insights into disease processes such as cancer, neurodegenerative disorders, and immune system dysregulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CX-4945 | 1009820-21-6 | sc-364475 sc-364475A | 2 mg 50 mg | $183.00 $800.00 | 9 | |
LCL161 inhibits IAPs, allowing caspases to become active and initiate apoptosis. It sensitizes tumor cells to death receptor signaling and promotes apoptosis by preventing the inhibition of caspases by IAPs. | ||||||
GDC 0152 | 873652-48-3 | sc-490087 | 5 mg | $388.00 | 1 | |
GDC-0152 acts as a bivalent IAP antagonist, binding to both the BIR3 domains of cIAP1 and cIAP2. This leads to the degradation of cIAP1/2, enabling caspase activation and apoptosis induction in cancer cells. | ||||||
Epz004777 | 1338466-77-5 | sc-507560 | 100 mg | $575.00 | ||
SM-406 selectively inhibits cIAP1, cIAP2, and XIAP. By disrupting the interaction between IAPs and caspases, it enables caspase activation and apoptosis induction in cancer cells, potentially inhibiting tumor growth. | ||||||